HN21C1061

Topical immunotherapeutic agent for atopic dermatitis : FPR2-selective pro-resolving peptide ligand

Novacell Technology Inc.

NOVACELL Technology

IMMUNOLOGY | **Phase 1**

Product Type	Peptide Product (7-mer, N-terminal lipidation)
Indication	• Primary indication: Atopic dermatitis, Dermatitis, Atopic [MeSH term] (Target patients: Mild-to-Moderate) • Secondary indication: Psoriasis, Dry eye syndrome (eye drop) [MeSH term] (Target patients: Mild-to-Severe)
Target	Formyl peptide Receptor 2 (FPR2)
MoA(Mechanism of Action)	NCP112 is a FPR2-specific peptide ligand acting as a pro-resolving factor through FPR2 activation
Differential Point	• First-in-class immunotherapeutic agent targeting FPR2, a validated molecular target to induce resolution of inflammation • Efficacy on characteristic symptoms of atopic dermatitis including skin inflammation, skin barrier disruption, and pruritus • Safety profile confirmed in Preclinical/Clinical study to meet unmet medical needs for long-term treatment as a topical agent • Convenient administration route for mild-to-moderate patients along with lower cost of treatment compared to biologics
Development Stage	Phase 1 (Application for Phase II clinical trial is scheduled on 1st quarter of 2023)
Route of Administration	Topical (Dermal)





kddf_bd@kddf.org
KDDF Business Development Team

KDDF Korea Drug Development Fund